TOKYO, May 19 (Pulse News Wire) – J-pharma CO.,LTD. (520A.T) reported a net loss of ¥--¥2.460 billion for the fiscal year ended March 2026, driven by research and development expenses totaling ¥3.010 billion.
The company continues to advance its global phase 3 clinical trials for Beacon-BTC, targeting pancreatic and biliary tract cancers, aiming for regulatory approval with a success probability of 12%. For the fiscal year ending March 2027, J-Pharma forecasts continued investment in three key projects, expecting operating losses of ¥--¥2.840 billion amid efforts to enhance patent protection and develop new LAT1 inhibitors.
The firm plans to construct commercialization strategies for its lead drug candidate, JPH034, leveraging accumulated evidence from multi-year collaborations with NINDS, Georgetown University, and Turku University. J-Pharma also highlighted progress on its NANBLRAT project, focusing on extending patents and exploring multiple partnership opportunities with pharmaceutical companies.
The company aims to initiate global phase 3 trials for NANBLRAT in the next fiscal year while maintaining a stable cash position of ¥4.450 billion and a solid capital ratio of 85.4%.
🟡 Confidence: Standard AI-translated content.